Asset Allocation

As of December 31, 2025.
Type % Net
Cash 0.00%
Stock 65.43%
Bond 33.93%
Convertible 0.00%
Preferred 0.00%
Other 0.64%
View Asset Allocation
Start Trial

Market Capitalization

As of December 31, 2025
Large 73.94%
Mid 15.27%
Small 10.79%
View Market Capitalization
Start Trial

Region Exposure

% Developed Markets: 97.33%    % Emerging Markets: 1.04%    % Unidentified Markets: 1.63%

Americas 84.49%
84.44%
Canada 1.83%
United States 82.61%
0.05%
As of December 31, 2025. Region breakdown data is calculated by using the long position holdings of the portfolio.
Greater Europe 12.20%
United Kingdom 2.07%
10.13%
Germany 1.08%
Ireland 3.67%
Netherlands 3.22%
Spain 0.15%
Sweden 0.05%
Switzerland 0.10%
0.00%
0.00%
Greater Asia 1.68%
Japan 0.46%
0.07%
Australia 0.07%
0.11%
Singapore 0.11%
1.04%
Philippines 1.04%
Unidentified Region 1.63%

Bond Credit Quality Exposure

AAA 26.05%
AA 16.84%
A 29.56%
BBB 19.84%
BB 0.00%
B 0.00%
Below B 0.00%
    CCC 0.00%
    CC 0.00%
    C 0.00%
    DDD 0.00%
    DD 0.00%
    D 0.00%
Not Rated 0.00%
Not Available 7.72%
Short Term 0.00%
As of December 31, 2025
View Bond Credit Quality Exposure
Start Trial

Stock Sector Exposure

Cyclical
27.54%
Materials
0.73%
Consumer Discretionary
9.32%
Financials
14.69%
Real Estate
2.80%
Sensitive
55.36%
Communication Services
12.82%
Energy
0.00%
Industrials
8.20%
Information Technology
34.33%
Defensive
15.93%
Consumer Staples
5.86%
Health Care
8.27%
Utilities
1.80%
Not Classified
1.17%
Non Classified Equity
0.00%
Not Classified - Non Equity
1.17%
As of December 31, 2025
View Region Exposure
Start Trial

Bond Sector Exposure

As of December 31, 2025
Type % Net
Government 13.23%
Corporate 80.31%
Securitized 0.00%
Municipal 6.46%
Other 0.00%
View Bond Sector Exposure
Start Trial

Bond Maturity Exposure

Short Term
6.41%
Less than 1 Year
6.41%
Intermediate
87.20%
1 to 3 Years
25.35%
3 to 5 Years
28.13%
5 to 10 Years
33.73%
Long Term
6.39%
10 to 20 Years
6.39%
20 to 30 Years
0.00%
Over 30 Years
0.00%
Other
0.00%
As of December 31, 2025
View Bond Maturity Exposure
Start Trial